Original Research

Published on 23 Apr 2024

Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era

in Hematologic Malignancies

Dong Won Baek
Ga-Young Song
Ho Sup Lee
Young Rok Do
Ji Hyun Lee
Ho-Young Yhim
Joon Ho Moon
Deok-Hwan Yang

Frontiers in Oncology

doi 10.3389/fonc.2024.1380492

1,079 views

Review

Published on 22 Apr 2024

Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing

in Hematologic Malignancies

Jianbiao Zhou
Wee-Joo Chng

Frontiers in Oncology

doi 10.3389/fonc.2024.1365330

3,115 views

Mini Review

Published on 22 Apr 2024

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

in Hematologic Malignancies

Yifan Pang
Nilanjan Ghosh

Frontiers in Oncology

doi 10.3389/fonc.2024.1396395

2,073 views
1 citation

Correction

Published on 18 Apr 2024

Corrigendum: Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study

in Hematologic Malignancies

Mojtaba Azari
Maryam Barkhordar
Tanaz Bahri
Soroush Rad
Hosein Kamranzadeh Fumani
Seied Asadollah Mousavi
Sahar Tavakoli Shiraji
Morteza Azari
Parisa Shafaroudi
Mohammad Vaezi

Frontiers in Oncology

doi 10.3389/fonc.2024.1397607

453 views

Review

Published on 18 Apr 2024

Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects

in Hematologic Malignancies

Charles J. Milrod
Ari Pelcovits
Thomas A. Ollila

Frontiers in Oncology

doi 10.3389/fonc.2024.1397053

1,718 views
1 citation

Brief Research Report

Published on 16 Apr 2024

A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing

in Hematologic Malignancies

Angelos Giannakoulas
Marios Nikolaidis
Grigorios D. Amoutzias
Nikolaos Giannakoulas

Frontiers in Oncology

doi 10.3389/fonc.2024.1390105

1,495 views
1 citation

Original Research

Published on 12 Apr 2024

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

in Hematologic Malignancies

Francesco Angotzi
Federica Lessi
Matteo Leoncin
Carla Filì
Mauro Endri
Albana Lico
Andrea Visentin
Stefano Pravato
Anna Candoni
Livio Trentin

Frontiers in Oncology

doi 10.3389/fonc.2024.1370405

1,805 views

Original Research

Published on 12 Apr 2024

Central venous catheters do not increase the hemorrhagic risk in acute promyelocytic leukemia patients during induction therapy

in Hematologic Malignancies

Manxiong Cao
Jiaqiong Hong
Dongqing Zhang
Feiheng Chen
Yongzhong Su

Frontiers in Oncology

doi 10.3389/fonc.2024.1332372

570 views

Original Research

Published on 11 Apr 2024

Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports

in Hematologic Malignancies

Philipp Faustmann
Jan C. Schroeder
Lucas Mix
Lennart Harland
Andreas Riedel
Wichard Vogel
Claudia Lengerke
Stefan Wirths

Frontiers in Oncology

doi 10.3389/fonc.2024.1384172

3,232 views
1 citation

Original Research

Published on 11 Apr 2024

Comparison of cytomorphology and histomorphology in myelodysplastic syndromes

in Hematologic Malignancies

Kathrin Nachtkamp
Corinna Strupp
Rosa Faoro
Norbert Gattermann
Sascha Dietrich
Ulrich Germing
Stefan Baldus

Frontiers in Oncology

doi 10.3389/fonc.2024.1359115

755 views

Case Report

Published on 11 Apr 2024

Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review

in Hematologic Malignancies

Polina Bellman
Jesus D. Gonzalez-Lugo
Moazzam Shahzad
Muhammad Kashif Amin
Muhammad Fareed Khalid
Nahid Suleman
Nausheen Ahmed
Anurag K. Singh
Abdulraheem Yacoub
Da Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1383730

1,648 views

Review

Published on 10 Apr 2024

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

in Hematologic Malignancies

Ricardo D. Parrondo
Sikander Ailawadhi
Claudio Cerchione

Frontiers in Oncology

doi 10.3389/fonc.2024.1394048

4,788 views
2 citations

Original Research

Published on 09 Apr 2024

Comparison of chemotherapy and chidamide combined with chemotherapy in patients with untreated angioimmunoblastic T-cell lymphoma

in Hematologic Malignancies

Simeng Gu
Xin Wang
Jingqiu Zhou
Shanshan Du
Ting Niu

Frontiers in Oncology

doi 10.3389/fonc.2024.1373127

837 views

Review

Published on 09 Apr 2024

Targeted therapy for multiple myeloma: an overview on CD138-based strategies

in Hematologic Malignancies

Federico Riccardi
Carmela Tangredi
Michele Dal Bo
Giuseppe Toffoli

Frontiers in Oncology

doi 10.3389/fonc.2024.1370854

3,275 views
4 citations

Systematic Review

Published on 08 Apr 2024

Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis

in Hematologic Malignancies

Han Xu
Chaoyang Guan
Peipei Xu
Dongming Zhou
Yong Xu
Bing Chen
Hua Bai

Frontiers in Oncology

doi 10.3389/fonc.2024.1355643

2,020 views
1 citation

Brief Research Report

Published on 08 Apr 2024

Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity

in Hematologic Malignancies

Daria Galas-Filipowicz
Selina J. Chavda
Jia-Nan Gong
David C. S. Huang
Asim Khwaja
Kwee Yong

Frontiers in Oncology

doi 10.3389/fonc.2024.1394393

1,625 views

Navigation group

Articles

Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era

Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Corrigendum: Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study

Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects

A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

Central venous catheters do not increase the hemorrhagic risk in acute promyelocytic leukemia patients during induction therapy

Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports

Comparison of cytomorphology and histomorphology in myelodysplastic syndromes

Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

Comparison of chemotherapy and chidamide combined with chemotherapy in patients with untreated angioimmunoblastic T-cell lymphoma

Targeted therapy for multiple myeloma: an overview on CD138-based strategies

Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis

Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity